Zoetis Inc. today announced the commercial launch of Portela (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. The launch addresses a critical need for long-term pain management in feline patients, particularly given the challenges of daily oral medication compliance and the tendency of cats to mask pain symptoms.

Backed by nearly a decade of science and research, Portela demonstrated effectiveness in alleviating OA pain in a pivotal nine-month European field study. Improvements were observed from as early as Day 3 after the first injection. By binding to a novel site on NGF, Portela enables up to three months of OA pain relief. In clinical trials, Portela was found to be well tolerated and demonstrated effectiveness in alleviating OA pain.

Significance of Osteoarthritis Pain

Osteoarthritis is a common, chronic, and progressive joint disease characterized by inflammation and breakdown of joints, leading to pain and mobility issues. Up to 40% of all cats may be clinically affected by OA, yet only 18% of affected cats are diagnosed with OA pain by veterinary professionals. Cats are naturally inclined to mask pain, and many owners interpret reduced activity or reluctance to jump as normal aging rather than signs of a treatable condition. Additionally, administering regular oral medication to cats presents a well-known compliance challenge, which results in many cats with OA going undertreated.

Clinical Evidence and Features

The efficacy of Portela is supported by a pivotal nine-month European field study. The study focused on the alleviation of OA pain in cats, with data showing improvements as early as Day 3 following the initial injection.

Strategic Portfolio Expansion

Portela expands Zoetis's portfolio of pain management solutions for companion animals. It joins Solensia (frunevetmab), an anti-NGF monoclonal antibody indicated for monthly alleviation of OA pain in cats. While Solensia requires monthly administration, Portela is designed to provide pain relief for a longer period of time by binding to a different site on NGF, offering the convenience of a single injection once every three months.

"Feline osteoarthritis remains one of the most underdiagnosed conditions in veterinary medicine, in part because cats instinctively hide signs of pain," said Jamie Brannan, Executive Vice President and Chief Commercial Officer of Zoetis. "Portela reinforces our commitment to closing that gap – giving veterinary professionals a long-acting injectable option specifically designed for cats – helping address day-to-day dosing challenges for some pet owners and supporting sustained pain management over time."

Safety and Usage

Portela should not be used in cats with known hypersensitivity to relfovetmab, or breeding, pregnant, or lactating cats, or cats less than 12 months of age. The most common side effect reported in the EU product label information is immediate pain upon injection, followed by dermatitis. Uncommon side effects included pruritus, skin scabs, injection site swelling, and injection site hair loss. In Canada, possible side effects include injection site pain, skin infection, hair loss, dermatitis, and decreased appetite.

An Australian regulatory watchdog has raised significant competition concerns over a proposed $160 million buyout in the agricultural and animal health sector. The Australian Competition and Consumer Commission (ACCC) recently determined that the planned acquisition of the global animal genomic testing business belonging to Neogen Corporation by Zoetis Inc. could substantially diminish market competition. Consequently, the regulatory body has decided that the transaction requires a thorough Phase 2 assessment before it can proceed.

Both companies currently serve as major providers of genomic testing services tailored for dairy cattle, beef cattle, and sheep within the Australian market. By absorbing the Neogen Genomics division, the acquiring firm would effectively consolidate a massive share of this highly specialized agricultural sector.

Data Monopoly And Market Influence Concerns

Beyond the immediate consolidation of diagnostic and testing services, the ACCC is actively evaluating the long-term implications of genetic data ownership. The regulatory agency is weighing the competitive impact of the acquiring company gaining exclusive access to a vastly increased breadth and volume of genetic data concerning Australian sheep and cattle populations following the acquisition.

Strategic Expansion And Precision Health Efforts

The global animal health leader initially announced this definitive agreement in March. The $160 million cash transaction, which remains subject to customary closing adjustments, was strategically designed to bolster the buyer’s Precision Animal Health portfolio. Corporate leadership emphasized that integrating these new assets aligns directly with a broader strategy to fuel future livestock innovation through advanced genomics.

Integrating the target company’s robust data solutions and cutting-edge genomic technologies was intended to significantly expand capabilities for delivering predictive insights and individualized care. The strategic integration aims to create greater added value for customers managing companion animals and major livestock species worldwide.

Global Reach And Operational Scale Of Neogen Genomics

The target genomics business currently operates on a vast international scale, effectively serving customers across more than 120 countries. Its operational infrastructure includes five dedicated laboratories located in the United States, the United Kingdom, China, Australia, and Brazil, functioning alongside a corporate office in Canada.

Recognized for its leadership in U.S. dairy and beef genomics, the division utilizes advanced software solutions alongside a comprehensive genotyping platform that features both sequencing and fixed-array technologies.